Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
11
Recruiting, industry sponsors, Infectious disease and vaccines, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed502
11 trials
Showing 1 to 11, recently updated first.
- A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)Pivotal-lookingRecruiting
Sinovac Biotech Co., LtdIndustry
NCT07832201 · 150 participants (planned) · Start Oct 20, 2026 · Primary completion Feb 2027
Drug: Anflu®; Vaxigrip® · For: Influenza
Sites: Changsha, China; Chengdu, China; Chongqing, China · 6 sites in all
- A Study of Updated mRNA Seasonal Influenza VaccinesPivotal-lookingRecruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07884175 · 200 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 7, 2026
Drug: mRNA-1010; Licensed High-Dose Seasonal Influenza Vaccine · For: Seasonal Influenza
Sites: Tucson, Arizona; Lenexa, Kansas; Louisville, Kentucky · 4 sites in all
- Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV)Pivotal-lookingRecruiting
Liaoning Chengda Biotechnology CO., LTDIndustry
NCT07932132 · 160 participants (planned) · Start Aug 8, 2026 · Primary completion Jun 30, 2027
Drug: Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried · For: Rabies; HIV Infections
Sites: Nanning, China · 2 sites in all
IMMUNOe Research CentersIndustry
NCT07932002 · 30 participants (planned) · Start Nov 5, 2025 · Primary completion Jul 31, 2027
Drug: Ruconest · For: Post SARS-CoV2 (COVID-19); Post-Viral Fatigue Syndrome; Post-Viral Disorder (Disorder) and 1 more
Sites: Centennial, Colorado
Gilead SciencesGilead Sciences (GILD)
NCT06337032 · 350 participants (planned) · Start Aug 27, 2024 · Primary completion Jun 2027
Drug: F/TAF (High Dose Tablet); F/TAF (Low Dose Tablet) and 19 more · For: HIV-1-infection
Sites: Buenos Aires, Argentina; Panama City, Panama; Cape Town, South Africa · 17 sites in all
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsPivotal-lookingRecruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07863635 · 600 participants (planned) · Start Oct 9, 2026 · Primary completion Dec 11, 2026
Drug: mRNA-1273; mRNA-1283 · For: SARS-CoV-2
Sites: Overland Park, Kansas; Louisville, Kentucky; Charlotte, North Carolina · 5 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07489573 · 36 participants (planned) · Start Jun 1, 2026 · Primary completion Sep 25, 2029
Drug: Secukinumab · For: Hidradenitis Suppurativa (HS)
Sites: Guangzhou, China; Shijiazhuang, China; Chengdu, China · 10 sites in all
- Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute DiarrheaRecruiting
Bausch Health Americas, Inc.Industry
NCT07285785 · 54 participants (planned) · Start Feb 11, 2026 · Primary completion Apr 20, 2027
Drug: Rifaximin 200 mg Tablet · For: Diarrhea; Gastroenteritis; Bacterial Infection and 1 more
Sites: Lynwood, California; Hialeah, Florida; Miami, Florida · 10 sites in all
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of AgePivotal-lookingRecruiting
BioNTech SEIndustry
NCT07730450 · 200 participants (planned) · Start Jul 23, 2026 · Primary completion Aug 20, 2027
Drug: BNT162b2 Vaccine; Tdap Vaccine · For: COVID-19 Vaccines
Sites: Walnut Creek, California; Miami Lakes, Florida; Honolulu, Hawaii · 5 sites in all
ModernaTX, Inc.Moderna (MRNA)
NCT06585241 · 1,144 participants (planned) · Start Sep 9, 2024 · Primary completion Dec 31, 2026
Drug: mRNA-1273 Variant-containing Formulation · For: SARS-CoV-2
Sites: Atlanta, Georgia; Decatur, Georgia; Baton Rouge, Louisiana · 6 sites in all
- Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))Pivotal-lookingRecruiting
BiocodexIndustry
NCT06451913 · 120 participants (planned) · Start Jul 16, 2025 · Primary completion Dec 2026
Drug: Amoxicillin + Saccharomyces boulardii CNCM I-745; Amoxicillin + Placebo · For: Erythema Migrans of Lyme Disease
Sites: Ljubljana, Slovenia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.